GlassScriptPhysician profile
Vladimir J Mathieu
NPI 1437212719
$37,158.14
in general payments reported to CMS, 2019-2025
63 companies · $7,640 in 2025
The $7,640 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,682 · 2020: $4,280 · 2021: $5,674 · 2022: $4,385 · 2023: $4,382 · 2024: $5,115 · 2025: $7,640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $1,705 · Travel and Lodging: $1,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,877.55 |
| Consulting Fee | $1,705.00 |
| Travel and Lodging | $1,554.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $4,082.15 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $4,045.59 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $3,985.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $2,518.08 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $2,418.45 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,322.06 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Amgen INC. | $2,108.77 | 2019-2025 | Otezla, Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $1,750.43 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $1,439.19 | 2019-2023 | |
| Lilly USA, LLC | $1,415.06 | 2019-2025 | Jardiance, Mounjaro, Kisunla |
| Merck Sharp & Dohme LLC | $1,238.24 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $926.99 | 2019-2025 | Xifaxan |
| Pfizer INC. | $657.61 | 2019-2025 | |
| Glaxosmithkline, LLC. | $631.00 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $617.25 | 2019-2024 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vladimir Mathieu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.